SEC Filing Analysis: SOPHiA GENETICS SA (SOPH)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Institutional investor Balderton Capital has reduced its stake in SOPHiA GENETICS below the 5% reporting threshold, signaling a significant reduction from its prior position.
• Market Impact: Neutral. While the exit of a large investor can be perceived negatively, it is common for venture capital and private equity firms to liquidate positions over time. The market may anticipate further selling of the remaining stake.

Company Information

Field	Value
Company	SOPHiA GENETICS SA
Ticker Symbol	SOPH
CIK	0001840706
Industry	Services-Computer Processing & Data Preparation

Insider Information

Field	Value
Name	Balderton Capital VI, S.L.P.
CIK	0001702178
Title/Position	Institutional Investor
Relationship	Former >5% Owner

Transaction Details

Field	Value
Form Type	SCHEDULE 13G/A
Transaction Date	N/A (Position as of 2025-12-31)
Transaction Code	N/A
Security Type	Ordinary Shares
Shares Involved	Not disclosed
Price Per Share	Not disclosed
Total Value	Not disclosed
Shares Owned After	3,301,240
Ownership Type	Indirect

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	Not Disclosed
% of Market Cap	Not Disclosed
Shares Transacted	Not Disclosed
% of Shares Outstanding	Not Disclosed
Post-Transaction Ownership	3,301,240 shares (4.9% of outstanding)
Materiality Assessment	Medium

Impact Evaluation

• Market Cap Context: For SOPHiA GENETICS, a small-cap company with a $330 million market capitalization, the reduction of a stake by a major venture backer like Balderton is a notable event.
• Ownership Concentration: This filing confirms that sales have occurred to bring Balderton's stake below the 5% reporting threshold. This action decreases ownership concentration and signals that an early investor is in the process of exiting its position.
• Transaction Significance: The key event is crossing below the 5% beneficial ownership threshold. This relieves the fund from the obligation of further 13G/D filings unless their stake increases again, and it informs the market that a large block of shares is no longer held by a major reporting entity.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This filing confirms a change in ownership status rather than a single, large market transaction. For a venture capital fund like Balderton, liquidating a position in a public company is a normal part of its fund lifecycle to return capital to its investors. It does not necessarily reflect a negative outlook on the company's fundamentals.

Volume & Sentiment

• Expected Volume Impact: The filing itself will likely have a minimal impact on volume. However, it confirms past selling pressure and suggests the remaining 4.9% stake could be sold in the future, potentially adding to supply.
• Sentiment Indicator: Neutral. The market often anticipates that early-stage investors will eventually sell their positions post-IPO.

Investment Insights

Positive Market Indicators

• None indicated by this filing.

Risk Factors

• An early, significant investor is continuing to liquidate its position.
• The remaining 4.9% stake, valued at approximately $16 million, could be sold on the open market, potentially creating a supply overhang and downward pressure on the stock price.

Key Takeaways

1. Balderton Capital has ceased to be a greater-than-5% beneficial owner in SOPHiA GENETICS.
2. This signals a significant, though not fully quantified, reduction in their investment.
3. The market may now view the remaining 3.3 million shares held by Balderton as a potential source of future selling pressure.

Additional Context

Transaction Notes

• This Schedule 13G/A (Amendment No. 3) reports the filer's beneficial ownership as of December 31, 2025. The filing is triggered by the filer's ownership percentage dropping below 5%.